Incyte Corporation
INCYHealthcareNASDAQBiotechnology · Last scanned Jul 16, 2026
Scan Results
Daily timeframeIncyte Corporation, a biopharmaceutical company, engages in the discovery, development, and commercialization of therapeutics in the United States, Europe, Canada, and Japan. The company carries a $22.99B market cap, placing it firmly in the large-cap category. The company offers JAKAFI for the treatment of myelofibrosis (MF), polycythemia vera, and steroid-refractory acute graft-versus-host disease; ICLUSIG, a kinase inhibitor to treat chronic myeloid leukemia and Philadelphia-chromosome positive acute lymphoblastic leukemia; MONJUVI/ MINJUVI for the treatment of diffuse large B-cell lymphoma and Follicular Lymphoma; NIKTIMVO for the treatment of chronic graft-versus-host disease.
Market Cap
$22.99B
Beta
0.76
P/E (TTM)
16.23
P/E (Fwd)
13.64
EPS (TTM)
$7.09
EPS (Fwd)
$8.44
ROE
30.8%
ROA
13.9%
Cash
$4.02B
Total Debt
$39.4M
Free CF
$558.9M
52W Change
66.2%
Annual Financials
Cash vs Debt
With $4.02B in cash and $39.4M in debt, INCY maintains more liquidity than leverage. This favorable balance sheet position can be an asset when capital markets become less accommodating. The company generates $558.9M in free cash flow annually, which funds everything from R&D to shareholder returns without needing external financing. Return on equity stands at 30.8%, which is exceptionally high for the sector. ROE measures how effectively a company uses shareholder capital to generate profits. Return on assets of 13.9% further supports the picture of efficient asset utilization. Revenue has grown from $3.39B (2022) to $5.14B (2025), reflecting a 51% increase over the period.
With cash comfortably exceeding debt, INCY has financial flexibility that may help navigate uncertain periods. These risk factors are not exhaustive — macroeconomic shifts, regulatory changes, and competitive dynamics can all influence Incyte Corporation's trajectory.